Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi,…
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology…
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…